Cost-effectiveness Analysis on Piperacillin/ Tazobactam and Cefoperazone/ Sulbactam in the Treatment of Bacterial Infection of Respiratory Tracts
- VernacularTitle:哌拉西林/三唑巴坦与头孢哌酮/舒巴坦治疗呼吸道细菌感染的成本-效果分析
- Author:
Xin LI
- Publication Type:Journal Article
- Keywords:
Bacterial infection of respiratory tract;
Piperacillin/tazobactam;
Cefoperazone/sulbactam;
Cost-effectiveness analysis
- From:
China Pharmacy
1991;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
0.05);The cost-effectiveness ratios were 2.29 and 1.84, respectively;The incremental cost-effectiveness ratio of the control group as against the trial group was 18.48. CONCLUSION: The therapy of piperacillin/tazobactam has marked pharmacoeconomics advantage over cefoperazone/sulbactam in treating bacterial infection of respiratory tracts.
